Arch. Dis. Child

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER


[Advanced]
Archives of Disease in Childhood - Fetal and Neonatal Edition 2007;92:F498-F502; doi:10.1136/adc.2005.092734
Copyright © 2007 BMJ Publishing Group Ltd & Royal College of Paediatrics and Child Health
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Read responses to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in ADC Online
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bose, C. L
Right arrow Articles by Laughon, M. M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bose, C. L
Right arrow Articles by Laughon, M. M
Topic Collections
Right arrowRelated Articles

REVIEW

Patent ductus arteriosus: lack of evidence for common treatments

Carl L Bose, Matthew M Laughon

Division of Neonatal-Perinatal Medicine, University of North Carolina, Chapel Hill, North Carolina, USA

Correspondence to:
Carl L Bose, Division of Neonatal-Perinatal Medicine, CB#7596, UNC Hospital, Chapel Hill, NC 27599-7596, USA; cbose{at}med.unc.edu


ABSTRACT
Patent ductus arteriosus (PDA) is a common diagnosis among extremely premature infants, especially in those with lung disease. Treatments are often used to close the PDA. Despite nearly three decades of research, the question of whether the benefits of treatments to prevent ductal patency or promote closure outweigh the risks of these treatments remains unanswered. The authors rarely use treatments designed to close the PDA. This article reviews three considerations in support of this restrained approach: rates of spontaneous closure of the ductus arteriosus; adverse effect of persistent ductal patency; and benefits and risks of treatments for closure.

Abbreviations: BPD, bronchopulmonary dysplasia; CLD, chronic lung disease; COX, cyclo-oxygenase; IVH, intraventricular haemorrhage; NEC, necrotising enterocolitis; PDA, patent ductus arteriosus

Keywords: patent ductus arteriosus; indomethacin; ibuprofen; ductal ligation


Related Articles

Fantoms
Martin Ward Platt
Arch. Dis. Child. Fetal Neonatal Ed. 2007 92: F423. [Extract] [Full Text] [PDF]

Towards rational management of the patent ductus arteriosus: the need for disease staging
Patrick J McNamara and Arvind Sehgal
Arch. Dis. Child. Fetal Neonatal Ed. 2007 92: F424-F427. [Extract] [Full Text] [PDF]



eLetters:

Read all eLetters

Conservative treatment of symptomatic patent ductus arteriosus beyond the first week of life
Jasper V Been, et al.
Fetal Neonatal Ed. Online, 21 Dec 2007 [Full text]

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
ARCH DIS CHILD FETAL NEONATAL ED ED PRACTICE
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2007 BMJ Publishing Group Ltd & Royal College of Paediatrics and Child Health